Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 9

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

"Neural” differentiation of bone marrow mesenchymal stem cells

100%
Rieske P.
Acta Neurobiologiae Experimentalis
|
2011
|
tom 71
|
nr 1
Therapeutic benefits of bone marrow MSCs use in the neurological disorders exist. Although, currently there is not a clear understanding of the detailed mechanisms by which MSCs mediate neural recovery. Early studies suggested that MSCs injected into the lateral ventricles of developing animals differentiated into neural cell types. However, latter data showed that appearance of GFAP positive MSCs derivatives was consequence of cells fusion. Moreover, older data suggesting transdifferentiation of mesenchymal stem cells into neural derivatives is poorly supported by the current data. Many of articles suggesting neural differentiation of bone marrow mesenchymal stem cells appeared as based on controversial, or even inconsistent data. Surprisingly, authors analyzing putative neural differentiation of bone marrow MSCc do not present corresponding results of neural differentiation of neural progenitors. Moreover, markers of neural differentiation can be misleading. To this end, neural differentiation of bone marrow mesenchymal stem cells should be considered as controversial.
2

Inducing efÞ cient catecholaminergic differentiation of GFAP, SOX2-positive neural progenitors (NHA) by means of kinetic factors

51%
Rieske P., Witusik M., Wolanczyk M., Krynska B.
Acta Neurobiologiae Experimentalis
|
2009
|
tom 69
|
nr 1
Extensive research has been performed to control differentiation of neural stem cells. For last three years we have strived to obtain stabilized protocol of catecholaminergic differentiation of GFAP, SOX2- positive neural progenitors (NHA) In 2007 we published fi rst results presenting differentiation of GFAP positive neural progenitors (NHA) in accordance to model of discordant phenotypes suppression (Rieske 2007, Eur J Neurosci). Since the beginning of 2008 we are able to differentiate uncommitted GFAP and SOX2 positive neural progenitors (NHA) in different environmental conditions to: only neural cells consisted of neuronal and glial cells, or fi broblast-like cells, or mixture of neural and fi broblast-like cells (Witusik 2007, Brain Res; Witusik 2008 BMC Biotechnol). In spite of successful blockade of fi broblast-like differentiation by means of environmental changes, we were able to barely increase the percentage of neuronal (GABA-ergic and catecholaminergic) over glial cells under several different cell culture testing conditions. It was so far also impossible to alter radically ratio catecholaminergic /GABA-ergic cells by means of changing environmental factors (SHH, GDNF, bFGF, EGF, BMPs). It strongly suggested infl uence of stochastic events or so called continuum processes during neuronal versus glial, and catecholaminergic versus GABA-ergic differentiation of described neural progenitors. Nevertheless including kinetic factors to our differentiation protocols allowed to increase percentage of catecholaminergic cells from 10 to 45% of neuronal cells.
3

Loss of heterozygosity for Rb locus and pRb immunostaining in laryngeal cancer: a clinicopathologic, molecular and immunohistochemical study

51%
Pietruszewska W., Klatka J., Borzecki A., Rieske P.
Folia Histochemica et Cytobiologica
|
2008
|
tom 46
|
nr 4
479-485
4

Inventing combination instead of reductionistic model, to control the process of GFAP positive, human neural progenitors differentiation

39%
Rieske P., Witusik M., Hulas-Bigoszewska K., Liberski P. P., Azizi S. A., Krynska B.
Acta Neurobiologiae Experimentalis
|
2006
|
tom 66
|
nr 4
5

The role of PrPc protein in neural differentiation of GFAP-positive NSCs into neuronal and glial line

39%
Witusik M., Kulas-Bigoszewska K., Krynska B., Azizi S. A., Liberski P. P., Rieske P.
Acta Neurobiologiae Experimentalis
|
2006
|
tom 66
|
nr 4
6

Prion protein gene (PRNP) codon 129 poiymorphism in Polish centenarians

33%
Sieruta M., Golanska E., Hulas-Bigoszewska K., Gresner S., Szybinska A., Styczynska M., Peplonska B., Barcikowska M., Rieske P., Liberski P. P.
Acta Neurobiologiae Experimentalis
|
2006
|
tom 66
|
nr 4
7

Gliomas: association of histology and molecular genetic analysis of chromosomes 1p, 10q, and 19q

33%
Gresner S. M., Rieske P., Wozniak K., Piaskowski S., Jaskolski D. J., Skowronski W., Sikorska B., Papierz W., Liberski P. P.
Acta Neurobiologiae Experimentalis
|
2007
|
tom 67
|
nr 2
The aim of our study was to evaluate the frequencies of loss of heterozygosity (LOH) on chromosomes 1p, 10q, and 19q in gliomas and to correlate them with the histological diagnosis and with patient age and gender. We found deletions within chromosome 1p to be significantly associated with the histological subtype of glial tumor (P<0.05); frequency of 1p deletions increased from astrocytoma (0%) through glioblastoma (31%) and oligoastrocytoma (57%) to oligodendroglioma (63%). In patients with 1p LOH, the odds for having astrocytoma or glioblastoma were approximately 10-fold and 4-fold lower, respectively, than oligodendroglioma. The odds for having oligoastrocytoma were similar to oligodendroglioma (OR=1.3). The frequency of 10q LOH in patients with glioblastoma was significantly higher than in patients with oligodendroglioma (89% vs. 36%; P<0.005). In patients with oligodendroglioma, most cases with LOH on chromosome 1p also had LOH 19q (90%), one case of 1p LOH also had a deletion on 10q. Statistical analyses revealed a significant association between deletions on 1p and 19q (P<0.05). Our data provide evidence that use of molecular genetic analyses of chromosomes 1p, 19q, and 10q might improve the diagnosis of gliomas.
8

In vitro cultured 3D aggregates of glioblastoma cells preserve in vivo observed phenotype and genotype of this tumour

27%
Witusik-Perkowska M., Bienkowski M., Jurga M., Stoczynska-Fidelus E., Hulas-Bigoszewska K., Roci I., McGuckin C. P., Banaszyk M., Wolanczyk M., Sikorska B., Liberski P. P., Rieske P.
Acta Neurobiologiae Experimentalis
|
2011
|
tom 71
|
nr 1
Surprisingly in vitro conditions allowing to culture glioblastoma cells presenting EGFR amplification were not known until now. Our evaluation of EGFR amplification status in glioblastoma (GBM) culture demonstrated that this anomaly was preserved for months in spheroids (aggregated glioblastoma cells) at a level comparable to the earliest passage of cell culture. In contrast, and in accordance with already published data we detected it as completely lost in the adherent culture. Apparently glioblastoma cells presenting EGFR amplification become apoptotic in the regular cell culture conditions. In addition discrepant expression of SOX2 and multilineage phenotype recognized as a markers of neural progenitors was observed in monolayer and 3D culture. Moreover, our analyses showed a decreased invasion potential of adherent GBM loosing EGFR amplification, and spheroids maintaining EGFR amplification. In conclusion, our findings confirm that GBM-derived spheroids seem to be a promising tool to preserve original molecular features of the tumor in vitro, with a special emphasis on EGFR gene aberrations, including EGFRvIII, regarded as novel therapeutic target. Our last unpublished and preliminary data suggest that mechanism responsible for in vitro death of adherent glioblastoma cells showing EGFR amplification seems to be linked to the artificial in vitro cell-cell interaction rather than to the lack of proper autocrine effects. Those suggestion came from analysis of glioblastoma cells in artificial brain tissues system and analysis of aggregated glioblastoma cells only. The present study was supported by the Ministry of Science and Higher Education, Poland, grant No. N N401047337 and Foundation for Polish Science(PARENT-BRIDGE Programme - support for women, No.POMOST_C/15).
9

EGFR involvement in neural and mesenchymal differentiation of glioblastoma progenitor cells

27%
Rieske P., Witusik P., Golanska E., Piaskowski S., Zakrzewski M., Gresner S., Jaskolski D. J., Zakrzewski K., Wolanczyk M., Krynska B., Hulas-Bigoszewska K., Szybka M., Kulczycka-Wojdala D., Liberski P. P.
Acta Neurobiologiae Experimentalis
|
2009
|
tom 69
|
nr 1
We have compared differentiation ability of glioblastoma cells with differentiation ability of neural progenitors. An effi cient differentiation arrest was observed in all cell lines isolated from glioblastomas in contrast to normal neural progenitors. However, cells isolated from six glioblastomas showed features of early stages of neural differentiation. Moreover, the cells derived from a majority of glioblastomas (8 out of 10) as well as neural progenitors showed features of non-neural (mesenchymal-like) differentiation. Moreover aggregated cells sustained EGFR amplifi cation, whereas cells grown as a monolayer did not. Cells showing EGFR amplifi cation became apoptotic grown as monolayer. Majority of mesenchymally differentiated glioblastoma cells showed features of senescence. Novel hypotheses which we would like to test are as follows: Neural progenitors could be a potential source of glioblastomas. Glioblastoma presents not only tumor stem cells but also tumor progenitor cells. Stable coexpression of glial and neuronal markers presented by glioblastoma cells results from differentiation arrest. Aggregating glioblastoma cells allows to sustain, EGFR amplifi cation in vitro. Moreover aggregated cells show proliferation ability, and differentiation arrest, whereas monolayer cells can be effi ciently differentiated and fi nally senescent. It suggests that simultaneous analysis of differentiation processes altogether with considering status of genes such as EGFR may help in designing new molecular targets for chemotherapy.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.